AVENUE THERAPEUTICS INC

For the period ended Dec 31, 2023. Filed Mar 18, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 18, 2024

ATXI$0.42-50.7%Stored close · as of Mar 18, 2025

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

Consolidated Statements of Changes in Stockholders’** Equity**

(In thousands, except share amounts)

Class A Preferred Stock · Common Shares · Additional paid-in · Accumulated · Non-Controlling · Total Stockholders’
	Shares	Amount	Shares	Amount	capital	deficit	Interests	equity
Balance at December 31, 2021	250,000	—	1,405,959	—	80,450	(76,999)	—	3,451
Share based compensation	—	—	75,505	—	649	—	—	649
Common shares issuable - Founders Agreement	—	—	—	—	526	—	—	526
Issuance of common shares and pre-funded warrants at private placement, net of issuance costs	—	—	3,636,365	—	3,205	—	—	3,205
Repurchase of common stock held by InvaGen	—	—	(388,888)	—	(1,104)	—	—	(1,104)
Fortress contribution of Baergic Inc	—	—	—	—	(99)	—	—	(99)
Issuance of subsidiaries’ common shares for license expenses	—	—	—	—	4	—	—	4
Exercise of warrants	—	—	44,900	—	237	—	—	237
Non-controlling interest in subsidiaries	—	—	—	—	588	—	(588)	—
Net loss attributable to non-controlling interest	—	—	—	—	—	—	(51)	(51)
Net loss attributable to common stockholders	—	—	—	—	—	(3,552)	—	(3,552)
Balance at December 31, 2022	250,000	$—	4,773,841	$—	$84,456	$(80,551)	$(639)	$3,266
Share based compensation	—	—	—	—	906	—	—	906
Issuance of common stock to Fortress	—	—	374,644	—	72	—	—	72
Common shares issuable - Founders Agreement	—	—	—	—	371	—	—	371
Issuance of common stock and pre-funded warrants, net of offering costs - November 2023 public offering	—	—	3,853,400	1	3,873	—	—	3,874
Issuance of common stock and pre-funded warrants, net of offering costs - registered direct offering and private placement	—	—	448,000	1	865	—	—	866
Issuance of common stock for license expense	—	—	1,108,270	—	1,230	—	—	1,230
Issuance of subsidiaries' common stock for license expenses	—	—	—	—	6	—	—	6
Exercise of warrants	—	—	14,272,382	1	—	—	—	1
Shares issued in a private placement offering	—	—	767,085	—	550	—	—	550
Non-controlling interest in subsidiaries	—	—	—	—	178	—	(178)	—
Net loss attributable to non-controlling interest	—	—	—	—	—	—	(111)	(111)
Net loss attributable to common stockholders	—	—	—	—	—	(10,377)	—	(10,377)
Balance at December 31, 2023	250,000	$—	25,597,622	$3	$92,507	$(90,928)	$(928)	$654

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.